|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PABPC1L |
Gene summary for PABPC1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PABPC1L | Gene ID | 80336 |
| Gene name | poly(A) binding protein cytoplasmic 1 like | |
| Gene Alias | C20orf119 | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80336 | PABPC1L | HCC1_Meng | Human | Liver | HCC | 7.29e-28 | 1.26e-01 | 0.0246 |
| 80336 | PABPC1L | HCC1 | Human | Liver | HCC | 8.30e-21 | 5.02e+00 | 0.5336 |
| 80336 | PABPC1L | HCC2 | Human | Liver | HCC | 5.94e-18 | 4.73e+00 | 0.5341 |
| 80336 | PABPC1L | S014 | Human | Liver | HCC | 4.84e-02 | 2.45e-01 | 0.2254 |
| 80336 | PABPC1L | S015 | Human | Liver | HCC | 2.37e-02 | 3.66e-01 | 0.2375 |
| 80336 | PABPC1L | S016 | Human | Liver | HCC | 1.91e-06 | 3.66e-01 | 0.2243 |
| 80336 | PABPC1L | S028 | Human | Liver | HCC | 2.63e-11 | 5.18e-01 | 0.2503 |
| 80336 | PABPC1L | S029 | Human | Liver | HCC | 3.29e-08 | 5.53e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa0301521 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa0301531 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PABPC1L | SNV | Missense_Mutation | c.784N>C | p.Tyr262His | p.Y262H | Q4VXU2 | protein_coding | deleterious(0.02) | possibly_damaging(0.857) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PABPC1L | SNV | Missense_Mutation | novel | c.1437G>C | p.Gln479His | p.Q479H | Q4VXU2 | protein_coding | tolerated(0.1) | benign(0.401) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| PABPC1L | SNV | Missense_Mutation | c.148N>T | p.Arg50Cys | p.R50C | Q4VXU2 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD | |
| PABPC1L | deletion | Frame_Shift_Del | novel | c.1172delN | p.Leu392Ter | p.L392* | Q4VXU2 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| PABPC1L | SNV | Missense_Mutation | c.1265N>A | p.Gly422Asp | p.G422D | Q4VXU2 | protein_coding | deleterious(0.02) | benign(0.028) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PABPC1L | SNV | Missense_Mutation | c.1478G>T | p.Gly493Val | p.G493V | Q4VXU2 | protein_coding | tolerated(0.08) | benign(0) | TCGA-BI-A20A-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PABPC1L | SNV | Missense_Mutation | novel | c.1531N>A | p.Ala511Thr | p.A511T | Q4VXU2 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-MY-A913-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PABPC1L | SNV | Missense_Mutation | c.1144N>C | p.Tyr382His | p.Y382H | Q4VXU2 | protein_coding | tolerated(0.11) | benign(0.172) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PABPC1L | SNV | Missense_Mutation | rs770697376 | c.1505N>T | p.Pro502Leu | p.P502L | Q4VXU2 | protein_coding | tolerated(0.06) | benign(0) | TCGA-AA-3697-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PABPC1L | SNV | Missense_Mutation | c.166N>C | p.Tyr56His | p.Y56H | Q4VXU2 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |